Exchange: NASDAQ·Updated 07:34 PM EDT
News
all
press releases
AMRX Down Despite Q2 Earnings Beat, 2026 Revenue Outlook Raised
Amneal tops second-quarter earnings and revenue estimates and lifts its 2026 outlook.
Zacks
More News
Wall Street Analysts Believe Repligen (RGEN) Could Rally 25.72%: Here's is How to Trade
The consensus price target hints at a 25.7% upside potential for Repligen (RGEN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks
Repligen Beats Q2 Earnings Estimates, Raises 2026 View, Stock Up
RGEN tops Q2 earnings and revenue estimates, lifts its 2026 revenue and EPS outlook, and sees shares jump after stronger-than-expected results.
Zacks
Repligen (RGEN) Beats Q2 Earnings and Revenue Estimates
Repligen (RGEN) delivered earnings and revenue surprises of +20.00% and +1.09%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
BioLife Solutions Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of BioLife Solutions, Inc. - BLFS
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the proposed sale of BioLife Solutions, Inc. (NasdaqCM: BLFS) to Repligen Corporation (NasdaqGS: RGEN). Under the terms of the proposed transaction, shareholders of...
Business Wire
Repligen to Expand Cell Therapy Capabilities With BioLife Buyout
RGEN's $1.5 billion BioLife acquisition aims to expand its cell therapy capabilities, adding biopreservation products and expected revenue and EPS benefits.
Zacks
Repligen To Acquire BioLife Solutions In $1.5 Billion Cash-and-Stock Deal
(RTTNews) - Repligen Corp. (RGEN), a life sciences company, on Wednesday agreed to acquire BioLife Solutions Inc. (BLFS) in cash-and-stock deal at approximately $1.5 billion, expanding its presence in the fast-growing cell therapy market...
Nasdaq News: Markets
Agenus (AGEN) Moves 82.7% Higher: Will This Strength Last?
Agenus (AGEN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zacks
Here's Why Repligen Corp. (RGEN) Fell 28% in Q1
Here's Why Repligen Corp. (RGEN) Fell 28% in Q1...
Yahoo! Finance: News
Repligen (RGEN) Dropped Following the Earnings Release
Repligen (RGEN) Dropped Following the Earnings Release...
Yahoo! Finance: News
<
1
2
>

Advertisement|Remove ads.